|1.||Adanja, G: 2 articles (07/2003 - 01/2003)|
|2.||Artiko, V: 2 articles (07/2003 - 01/2003)|
|3.||Petrovic, N: 1 article (07/2003)|
|4.||Pesko, P: 1 article (07/2003)|
|5.||Krivokapic, Z: 1 article (07/2003)|
|6.||Davidovic, B: 1 article (07/2003)|
|7.||Milosavljevic, T: 1 article (07/2003)|
|8.||Djukic, V: 1 article (07/2003)|
|9.||Obradovic, V: 1 article (07/2003)|
|10.||Petrovic, M: 1 article (07/2003)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
09/01/1998 - "The combination of In 111 CYT-103 and CYT-372 improved the sensitivity of external immunoscintigraphy for the detection of colorectal cancer compared to that obtained with a single MoAb imaging. "
08/01/1991 - "111In-CYT-103 immunoscintigraphic findings were consistent with the pathologic diagnoses for 70% of patients with colorectal cancer and 90% of disease-free patients. "
03/01/2002 - "The results of clinical studies with 111In-CYT-103 in detecting the occurrence of colorectal carcinoma provided additional information, making this method a valuable complementary test that contributes to patient management."
08/01/1991 - "The results of this study suggest that 111In-CYT-103 is a useful diagnostic tool for the presurgical evaluation of colorectal cancer patients."
01/01/1991 - "The results of this study indicate that monoclonal antibody imaging using [111In]CYT-103 is useful for the preoperative evaluation of colorectal carcinoma patients and the results are complimentary to CT of the abdomen and the pelvis."
|2.||Ovarian Neoplasms (Ovarian Cancer)
03/01/1993 - "The results of this trial indicate that 111In-CYT-103 immunoscintigraphy should be a valuable addition to the presurgical evaluation of patients with suspected persistent or recurrent ovarian cancer."
03/01/1993 - "The results of this trial also indicate that 111In-CYT-103 immunoscintigraphy can contribute to the medical and surgical management of some patients with ovarian cancer. "
12/01/1995 - "111In, oncoscint for colorectal and ovarian cancer imaging, has been approved for single use only, and is a product licensed by the Food and Drug Administration. "
10/01/1994 - "Food and Drug Administration has approved 111In satumomab pendetide (OncoScint CR/OV; Cytogen Corporation, Princeton, NJ) for use in imaging colorectal and ovarian cancer. "
06/11/1993 - "Oncoscint for detection of disseminated colorectal and ovarian cancer."
06/01/1993 - "The results of this study indicate that immunoscintigraphy using In-111 CYT-103 is more sensitive than CT and may add useful information to the preoperative evaluation of women with ovarian carcinoma."
08/01/1999 - "A retrospective study was carried out to determine the diagnostic value of OncoScint CR/OV immunoscintigraphy in assessing patients with suspected recurrence of carcinoma of the colon and ovary. "
03/01/1995 - "However, Oncoscint demonstrated an advantage in the detection of carcinomatosis. "
03/01/1995 - "Twelve patients who were examined for recurrent colorectal or ovarian carcinoma underwent both In-111 OncoScint imaging and F-18 FDG PET imaging. "
03/01/1995 - "Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. "
03/01/2002 - "To determine the effectiveness of radioimmunoscintigraphy (RIC) with 111In-CYT-103 in detecting the extension of malignant disease in patients surgically treated for colorectal adenocarcinoma under suspicion of recurrence in comparison to CT scan (computed tomography) and exploratory laparotomy. "
03/01/1993 - "111In-CYT-103 immunoscintigraphy correctly identified surgically confirmed tumor in 68% of patients with ovarian adenocarcinoma. "
09/01/1996 - "In the subgroup of 10 patients enrolled in the second part of the study, primary intestinal adenocarcinomas were imaged in five of five patients with 123I-VIP and in only two of these patients with 111In-CYT-103. "
09/01/1996 - "In this study, we have compared the in vitro and in vivo binding of 123I-VIP and of the 111In-labeled monoclonal antibody (MAb) directed against TAG-72 (OncoScint; 111In-CR-103) in patients with intestinal adenocarcinomas in a single-blinded, prospectively randomized trial. "
|5.||Neoplasm Metastasis (Metastasis)
05/01/1996 - "A single patient did not undergo surgery because of presence of pulmonary metastases identified on CT scan but not identified on a 111In-CYT-103 scan. "
02/01/1994 - "It failed to detect two primary lesions and one case of peritoneal metastasis, all of which were imaged by CYT-103. "
01/01/1992 - "Another limitation of 111In-CYT-103 immunoscintigraphy is in the identification of liver metastases.(ABSTRACT TRUNCATED AT 400 WORDS)"
01/01/1992 - "111In-CYT-103 imaging sensitivity was similar in patients with primary and recurrent disease, but lower for liver metastases than for extrahepatic disease. "
12/01/2001 - "Use of OncoScint scan to assess resectability of hepatic metastases from colorectal cancer."
|1.||Indium 111In-satumomab pendetide
|3.||tumor-associated antigen 72
|4.||iodinated vasoactive intestinal peptide
|7.||Immunoglobulin G (IgG)
|10.||Muromonab-CD3 (Muromonab CD3)